| Literature DB >> 18392862 |
Luis Costa1, Xavier Badia, Edward Chow, Allan Lipton, Andrew Wardley.
Abstract
INTRODUCTION: Skeletal-related events (SREs) from malignant bone disease cause considerable morbidity and can dramatically reduce patients' quality of life. DISCUSSION: Pathologic fractures often require surgical intervention and palliative radiotherapy. Thus, patients suffer impaired mobility, loss of functional independence, and diminished health-related quality of life (HRQOL). Bisphosphonates can delay the onset and reduce the incidence of SREs and have become the standard of care for the treatment of malignant bone disease; however, minimal information on the effects of bisphosphonate treatment on HRQOL is available. Targeted HRQOL assessments for patients with malignant bone disease are currently under development and are discussed herein.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18392862 DOI: 10.1007/s00520-008-0418-0
Source DB: PubMed Journal: Support Care Cancer ISSN: 0941-4355 Impact factor: 3.359